What Was Approved?
On May 15, 2026, the U.S. Food and Drug Administration approved Baxfendy (baxdrostat) for the treatment of hypertension in adults whose blood pressure is not adequately controlled with other medications.
Baxfendy is used in combination with other antihypertensive drugs.
How Does Baxfendy Work?
Baxfendy is an aldosterone synthase inhibitor.
Aldosterone is a hormone that can promote sodium and water retention and contribute to higher blood pressure.
By reducing aldosterone production, baxdrostat helps lower blood pressure.
How Is Baxfendy Taken?
The usual recommended dose is 2 mg by mouth once daily, with or without food.
For patients at increased risk of high potassium or low sodium, the recommended starting dose is 1 mg once daily.
What Are the Main Safety Concerns?
The FDA-approved label highlights two important electrolyte problems:
- Hyperkalemia, or high potassium
- Hyponatremia, or low sodium
Blood potassium and sodium should be checked before treatment and monitored during therapy.
What Is the Most Common Side Effect?
The most common adverse reaction reported more often than with placebo was hyperkalemia.
Certain medicines that also increase potassium may raise this risk further.
Does Baxfendy Replace Other Blood Pressure Medicines?
No.
The FDA-approved indication is specifically for use with other antihypertensive medications when blood pressure remains inadequately controlled.
Treatment should be individualized based on blood pressure, kidney function, electrolyte levels, and other medications.
Bottom Line
Baxfendy (baxdrostat) is a newly FDA-approved once-daily medication for adults with hypertension that remains inadequately controlled on other treatments.
Because it can affect potassium and sodium levels, laboratory monitoring is an important part of treatment.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Baxfendy (baxdrostat) Prescribing Information, revised May 2026.